Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.
The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.
Looking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。